NAFAMOSTAT

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H17N5O2
Molecular Weight	347.3706
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=N)NC1=CC=C(C=C1)C(=O)OC2=CC=C3C=C(C=CC3=C2)C(N)=N

InChI

InChIKey=MQQNFDZXWVTQEH-UHFFFAOYSA-N

InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)

HIDE SMILES / InChI

Molecular Formula	C19H17N5O2
Molecular Weight	347.3706
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35600 | https://www.ncbi.nlm.nih.gov/pubmed/8713783 | https://www.ncbi.nlm.nih.gov/pubmed/8029816

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has anticoagulant and anti-inflammatory properties. Nafamostat is approved and marketed in Japan. It relieves symptoms such as pain due to inflammation of the spleen. It improves visceral disorders and bleeding tendency caused by blood clotting tendency in the vessels. It prevents coagulation in the blood circuit during hemodialysis. It is usually used to improve acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation phase of chronic pancreatitis, post-operative acute pancreatitis, acute pancreatitis after pancreatography, traumatic pancreatitis) and to prevent disseminated intravascular coagulation (DIC) and clotting of perfusing blood in extracorporeal blood circuit. Nafamostat mesilate significantly inhibits the release of platelet beta-thromboglobulin (beta TG) at 60 and 120 min. Nafamostat mesilate (NM) prevents any significant release of neutrophil elastase; at 120 min, plasma elastase-alpha 1-antitrypsin complex is 0.16 mg/mL in the NM group and 1.24 mg/mL in the control group. Nafamostat mesilate completely inhibits formation of complexes of C1 inhibitor with kallikrein and FXIIa.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Trypsin I 2 Target ID: CHEMBL209 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10206542 \| https://www.ncbi.nlm.nih.gov/pubmed/9544206	Inhibitor 8504	17.0 nM [IC50]
Complement C1r 2 Target ID: CHEMBL4611 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10206542 \| https://www.ncbi.nlm.nih.gov/pubmed/9544206	Inhibitor 8504	12.0 µM [IC50]
Tryptase beta-1 2 Target ID: CHEMBL2617 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12939527	Inhibitor 8504	95.3 pM [Ki]
Transient receptor potential cation channel subfamily M member 7 6 Target ID: CHEMBL1250412 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21122141	Inhibitor 8504	617.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pancreatitis 16 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25822153 https://www.ncbi.nlm.nih.gov/pubmed/21206331	Primary		Approved 8583	NAFAMOSTAT Approved Use This medicine relieves symptoms such as pain due to inflammation of the spleen. It improves visceral disorders and bleeding tendency caused by blood clotting tendency in the vessels. It prevents coagulation in the blood circuit during hemodialysis. It is usually used to improve acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation phase of chronic pancreatitis, post-operative acute pancreatitis, acute pancreatitis after pancreatography, traumatic pancreatitis) and to prevent disseminated intravascular coagulation (DIC) and clotting of perfusing blood in extracorporeal blood circuit.
Disseminated intravascular coagulation 8 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26466700 https://www.ncbi.nlm.nih.gov/pubmed/11372771	Preventing		Approved 8583	NAFAMOSTAT Approved Use This medicine relieves symptoms such as pain due to inflammation of the spleen. It improves visceral disorders and bleeding tendency caused by blood clotting tendency in the vessels. It prevents coagulation in the blood circuit during hemodialysis. It is usually used to improve acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation phase of chronic pancreatitis, post-operative acute pancreatitis, acute pancreatitis after pancreatography, traumatic pancreatitis) and to prevent disseminated intravascular coagulation (DIC) and clotting of perfusing blood in extracorporeal blood circuit.

C_max

Value	Dose	Analyte	Population
16.4 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
61.5 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
93.2 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	40 mg single, intravenous dose: 40 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
14.49 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
40.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
60.43 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	40 mg single, intravenous dose: 40 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1655.84 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3571.14 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6880.46 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	40 mg single, intravenous dose: 40 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
23.1 min OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=23	40 mg single, intravenous dose: 40 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
112.42 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
128.19 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
122.91 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18392693/	40 mg single, intravenous dose: 40 mg route of administration: Intravenous experiment type: SINGLE co-administered:	NAFAMOSTAT plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
33.36% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/530169_3999407D1181_2_008_1F.pdf#page=24			NAFAMOSTAT serum	Homo sapiens

Doses

Dose	Population	Adverse events
20 mg single, intravenous Studied dose Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33495919/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33495919/	Other AEs: Hyperkalemia... Other AEs: Hyperkalemia (0.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/33495919/
50 mg single, intravenous Studied dose Dose: 50 mg Route: intravenous Route: single Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21775918/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21775918/	Sources: https://pubmed.ncbi.nlm.nih.gov/21775918/
1200 ug/kg/h single, intravenous Studied dose Dose: 1200 ug/kg/h Route: intravenous Route: single Dose: 1200 ug/kg/h Sources: https://pubmed.ncbi.nlm.nih.gov/1554918/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1554918/	Sources: https://pubmed.ncbi.nlm.nih.gov/1554918/

AEs

AE	Significance	Dose	Population
Hyperkalemia	0.7%	20 mg single, intravenous Studied dose Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: https://pubmed.ncbi.nlm.nih.gov/33495919/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33495919/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OCT2 434 P-gp 2052 OCTN1 55 OCTN2 59

Drug as victim

Target	Modality	Activity
OCTN1 55	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/14705184/	no
OCTN2 59	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/14705184/	no
P-gp 2052	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwOTE4NDEifX0=	no
OCT2 434	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/14705184/	yes [IC50 20 uM]

PubMed

Title	Date	PubMed
Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.	2007-12	17337140
Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death.	2007-05-15	17410536
Low-volume continuous hemodiafiltration with nafamostat mesilate increases trypsin clearance without decreasing plasma trypsin concentration in severe acute pancreatitis.	2007-04-07	17413562
Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7.	2007-04	17414427
[Anticoagulation of extracorporeal circuit in critically ill patients].	2007-03-08	17342691
Pancreatic enzymes generate cytotoxic mediators in the intestine.	2007-03	17304111
Implantation Serine Proteinases heterodimerize and are critical in hatching and implantation.	2006-12-11	17156484
Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells.	2006-11	17072764
Anticoagulation and continuous renal replacement therapy.	2006-08-09	16893409
Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis.	2006-08	16803693
[Prostasin].	2006-07	16895180
Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma.	2006-07	16815145
Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.	2006-06-09	16760715
Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat.	2006-06	16645332
Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.	2006-05-11	16551494
Human complement-activating immunoglobulin (Ig)G3 antibodies are essential for porcine endothelial cell activation.	2006-05	16756564
[Postoperative acute pulmonary thromboembolism treated with nafamostat mesilate].	2006-05	16715921
Complement activation is involved in biological responses to leukocyte adsorptive apheresis.	2006-05	16642423
Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis.	2006-04	16702735
Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.	2006-04	16612309
The role of a protease inhibitor against hepatectomy.	2006-03-02	16506388
Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications.	2006-02	16556137
Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice.	2006-01-13	16359660
[Quality of life in surgical treatment of pancreatic cancer].	2006-01	16457272
Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.	2006-01	16377383
JPN Guidelines for the management of acute pancreatitis: medical management of acute pancreatitis.	2006	16463210
Involvement of neutrophil recruitment and protease-activated receptor 2 activation in the induction of IL-18 in mice.	2005-11	16260585
Small volume resuscitation with hypertonic saline is more effective in ameliorating trauma-hemorrhagic shock-induced lung injury, neutrophil activation and red blood cell dysfunction than pancreatitic protease inhibition.	2005-08	16294064
Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners.	2005-08	16093613
Nafamostat mesilate induces production of interleukin-12 and -18 in human peripheral blood mononuclear cells.	2005-08	16093612
Effect of intraportal infusion to improve small for size graft injury in living donor adult liver transplantation.	2005-08	16008741
Open heart surgery in a patient with paroxysmal nocturnal hemoglobinuria.	2005-06	15997761
Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.	2005-04	15797071
Correlation between serum nafamostat mesilate and activated coagulation time during continuous hemodiafiltration.	2005-04	15787634
Rat experimental model of continuous regional arterial infusion of protease inhibitor and its effects on severe acute pancreatitis.	2005-04	15782103
[A patient with Vibrio vulnificus meningoencephalitis].	2005-01	15714995
Physiology and pathophysiology of proteinase-activated receptors (PARs): role of tryptase/PAR-2 in vascular endothelial barrier function.	2005-01	15655299
A serine protease inhibitor, nafamostat mesilate, suppresses aldosterone secretions in vivo.	2004-12	15894839
A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.	2004-12	15564710
[Continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis].	2004-11	15552895
[Treatment of acute pancreatitis with protease inhibitor, H2 receptor antagonist and somatostatin analogue].	2004-11	15552889
Pancreatic proteases and inflammatory mediators in peritoneal fluid during splanchnic arterial occlusion and reperfusion.	2004-11	15489640
Continuous hemodiafiltration in pediatric critical care patients.	2004-10	15663534
[Role of pancreatic enzymes in gut injury secondary to trauma/hemorrhagic shock in rats].	2004-10	15485785
Advanced glycation end products induce secretion of chemokines and apoptosis in human first trimester trophoblasts.	2004-09	15243005
[Pregnancy and delivery in patients with hemodialysis].	2004-06	15250340
[Heparin-induced thrombocytopenia in patients on hemodialysis].	2004-06	15250315
[Treatment of uremic patients with high bleeding risk].	2004-06	15250271
[Blood purification for patients with chronic renal failure accompanied by severe liver disease].	2004-06	15250270
Effects of anti-inflammatory cytokine agent (FR167653) and serine protease inhibitor on warm ischemia-reperfusion injury of the liver graft.	2004-05-27	15239609

Patents

Sample Use Guides

In Vivo Use Guide

Acute Kidney Injury: Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.

Route of Administration: Intravenous

In Vitro Use Guide

Nafamostat inhibited extrinsic pathway activity (TF-F.VIIa mediated-F.Xa generation) in a concentration dependent manner; the IC50 was 1.0 x 10(-7) M. Nafamostat inhibited TF-F.VIIa complex activity with an IC50 of 1.5 x 10(-7) M.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:11:26 GMT 2025` Edited by `admin` on `Mon Mar 31 18:11:26 GMT 2025`
Record UNII	Y25LQ0H97D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENZOIC ACID, 4-((AMINOIMINOMETHYL)AMINO)-, 6-(AMINOIMINOMETHYL)-2-NAPHTHALENYL ESTER

Preferred Name

English

NAFAMOSTAT

Official Name

English

Nafamostat [WHO-DD]

Common Name

English

nafamostat [INN]

Common Name

English

NAFAMOSTAT [MI]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

835721